232 related articles for article (PubMed ID: 21320608)
1. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.
Aggarwal M; Duan W; Hou Z; Rakesh N; Peng Q; Ross CA; Miller MI; Mori S; Zhang J
Neuroimage; 2012 May; 60(4):2086-95. PubMed ID: 22342677
[TBL] [Abstract][Full Text] [Related]
3. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images.
Zhang J; Peng Q; Li Q; Jahanshad N; Hou Z; Jiang M; Masuda N; Langbehn DR; Miller MI; Mori S; Ross CA; Duan W
Neuroimage; 2010 Feb; 49(3):2340-51. PubMed ID: 19850133
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
6. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
7. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
[TBL] [Abstract][Full Text] [Related]
8. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.
Hobbs NZ; Henley SM; Ridgway GR; Wild EJ; Barker RA; Scahill RI; Barnes J; Fox NC; Tabrizi SJ
J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):756-63. PubMed ID: 19955112
[TBL] [Abstract][Full Text] [Related]
9. Resting-state functional MRI reveals altered brain connectivity and its correlation with motor dysfunction in a mouse model of Huntington's disease.
Li Q; Li G; Wu D; Lu H; Hou Z; Ross CA; Yang Y; Zhang J; Duan W
Sci Rep; 2017 Dec; 7(1):16742. PubMed ID: 29196686
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
12. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.
Rattray I; Smith E; Gale R; Matsumoto K; Bates GP; Modo M
PLoS One; 2013; 8(4):e60012. PubMed ID: 23593159
[TBL] [Abstract][Full Text] [Related]
13. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
[TBL] [Abstract][Full Text] [Related]
15. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
16. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
17. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.
Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J
J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Chiu CT; Liu G; Leeds P; Chuang DM
Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.
Ruocco HH; Bonilha L; Li LM; Lopes-Cendes I; Cendes F
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):130-5. PubMed ID: 17615168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
